Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More…
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees24,000
Next Earnings Date2/20/2020 (Confirmed)
OptionableOptionable
Syneos Health (NASDAQ:SYNH) Frequently Asked Questions
What is Syneos Health's stock symbol?
Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."
How were Syneos Health's earnings last quarter?
Syneos Health Inc (NASDAQ:SYNH) issued its earnings results on Thursday, October, 31st. The company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.82 by $0.05. The firm had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.18 billion. Syneos Health's revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.75 earnings per share. View Syneos Health's Earnings History.
When is Syneos Health's next earnings date?
How can I listen to Syneos Health's earnings call?
Syneos Health will be holding an earnings conference call on Thursday, February 20th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Syneos Health issued on next quarter's earnings?
Syneos Health issued an update on its FY 2020
After-Hours earnings guidance on Wednesday, January, 15th. The company provided earnings per share (EPS) guidance of 3.58-3.78 for the period, compared to the Thomson Reuters consensus estimate of $3.59. The company issued revenue guidance of $4.88-5 billion, compared to the consensus revenue estimate of $4.94 billion.
What price target have analysts set for SYNH?
10 equities research analysts have issued 12-month target prices for Syneos Health's stock. Their forecasts range from $48.00 to $75.00. On average, they expect Syneos Health's stock price to reach $65.75 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Syneos Health.
What is the consensus analysts' recommendation for Syneos Health?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syneos Health.
Has Syneos Health been receiving favorable news coverage?
Headlines about SYNH stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Syneos Health earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Syneos Health.
What other stocks do shareholders of Syneos Health own?
Who are Syneos Health's key executives?
Syneos Health's management team includes the folowing people:
- Mr. Alistair Macdonald, CEO & Director (Age 49)
- Mr. Jason M. Meggs, Chief Financial Officer (Age 43)
- Mr. Jonathan Olefson, Gen. Counsel & Corp. Sec. (Age 43)
- Mr. Michael Adam Bell, Consultant (Age 63)
- Mr. Robert Parks, Exec. VP & Chief Accounting Officer
Who are Syneos Health's major shareholders?
Syneos Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ArrowMark Colorado Holdings LLC (2.23%), State Street Corp (1.92%), Bank of New York Mellon Corp (1.51%), Goldman Sachs Group Inc. (1.44%), Boston Partners (1.25%) and GW&K Investment Management LLC (1.05%). Company insiders that own Syneos Health stock include Alistair Macdonald, H Lee Equity Fund Vi Thomas, Jason M Meggs and Jonathan Olefson. View Institutional Ownership Trends for Syneos Health.
Which institutional investors are selling Syneos Health stock?
SYNH stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Principal Financial Group Inc., Prudential Financial Inc., Sei Investments Co., Goldman Sachs Group Inc., Boston Partners, Rothschild & Co. Asset Management US Inc. and SG Americas Securities LLC. View Insider Buying and Selling for Syneos Health.
Which institutional investors are buying Syneos Health stock?
SYNH stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Jennison Associates LLC, Hennessy Advisors Inc., Barclays PLC, Knights of Columbus Asset Advisors LLC, ArrowMark Colorado Holdings LLC, Magnetar Financial LLC and M&G Investment Management Ltd.. Company insiders that have bought Syneos Health stock in the last two years include Jason M Meggs and Jonathan Olefson. View Insider Buying and Selling for Syneos Health.
How do I buy shares of Syneos Health?
Shares of SYNH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Syneos Health's stock price today?
One share of SYNH stock can currently be purchased for approximately $65.62.
MarketBeat Community Rating for Syneos Health (NASDAQ SYNH)
MarketBeat's community ratings are surveys of what our community members think about Syneos Health and other stocks. Vote "Outperform" if you believe SYNH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYNH will underperform the S&P 500 over the long term. You may vote once every thirty days.
